What Intellia Therapeutics, Inc. told the SEC could break it.

Intellia is a clinical-stage company with all candidates in preclinical/clinical development and no certainty of significant product revenue; it has funded operations through its IPO, follow-on offerings, ATM sales ($128.2M in 2025) and convertible preferred stock, making it dependent on continued capital access.

“Even if the Company's product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.”

December 2025 CMS proposed rules (the GLOBE model for Medicare Part B and GUARD model for Part D) would apply 'most favored nation' international-reference pricing to single-source drugs and sole-source biologics; Intellia's lead in-vivo candidates likely fall under Medicare Part B, exposing future pricing to mandated rebates.

“The first proposal, the Global Benchmark for Efficient Drug Pricing Model (“GLOBE”) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS's spending and eligibility criteria. It is likely that our lead in vivo product candidates will fall under Medicare Part B.”